Abstract
Omalizumab is the monoclonal antibody against IgE, which blocks the binding of IgE to receptors on effector cells and this way blocks or decreases allergic reaction and asthma symptoms. Nowadays omalizumab is registered in the USA and European Union including Poland for treatment of patients with severe persistent, uncontrolled asthma. It is very effective in the reduction of asthma exacerbations, hospitalizations and emergency visits, it decreases intensity of symptoms and improves the quality of life. But omalizumab has more extensive action; given subcutaneously it has systemic effect. The article is the review of the studies and case reports on usage of omalizumab in new indications. Some authors’ own experiences in this field are also presented.